Remove FDA Remove Immunization Remove Pharmaceutical Companies
article thumbnail

FDA Approvals: September 2022 Recap

Digital Pharmacist

CDER relies on its understanding of science and regulatory procedures to support and provide advice to pharmaceutical companies in testing and manufacturing, to then bring these new therapies to the market to aid patients and their health. The FDA granted the approval of Relyvrio to Amylyx Pharmaceuticals Inc.

FDA 75
article thumbnail

Innovation in biosimilars: Leading companies in neuro-degenerative receptor binding drug compositions

Pharmaceutical Technology

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. AC Immune and F. Hoffmann-La Roche are the other key patent filers in neuro-degenerative receptor binding drug compositions.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Incannex engages QPS for CannQuit and ReneCann

Pharmaceutical Technology

Australian pharmaceutical company Incannex has appointed Quest Pharmaceutical Services (QPS) to advance CannQuit-N (Nicotine), CannQuit-O (Opioid) and Renecann Products in the USA and the European Union (EU). French company Eurofins Scientific is currently developing and manufacturing both products.

article thumbnail

Data-crunching specialist CytoReason signs $110m Pfizer alliance

pharmaphorum

The two companies have been talking to each other since 2017 and formally working together since 2019, when Pfizer started using CytoReason’s biological models in research aimed at developing new drugs for immune-mediated diseases and cancer immunotherapies.

article thumbnail

The future of targeted alpha therapy development and manufacture

European Pharmaceutical Review

Lastly, there is growing prominence and interest in radioligand therapeutics within major pharmaceutical companies, who are increasingly investing in this field, evident through recent acquisitions of Point Biopharma and RayzeBio. What makes targeted alpha therapies a promising new approach against cancer?

article thumbnail

Genmab and argenx team up to engineer novel antibody therapies

Pharmaceutical Technology

Pharmaceutical company Genmab is entering a partnership with argenx to develop antibody therapies for oncology and immunology. This collaboration is being made to combine the companies’ capabilities to develop novel therapeutic antibodies with applications in the two disease areas.

article thumbnail

Sanofi offers refunds for Cablivi in novel model for rebates

Pharmaceutical Technology

The program follows the lead of Pfizer’s warranty programs for Panzyga (immune globulin intravenous) and Xalkori (crizotinib), as pharma continues to explore new types of risk sharing agreements. Cablivi stops platelets from clumping together, which prevents small clots, and can be used along with other drugs that suppress the immune system.